uMotif, the data capture company putting patients at the centre of clinical research, has raised £2.4 million in its latest funding round led by Albion Capital, the leading independent investment manager, along with several angel investors.
uMotif’s software platform provides the patient-facing technology required to capture real-world data (eCOA, ePRo, eConsent) for the next generation of clinical research initiatives – from early phase to post-marketing trials. The technology is already in use by top pharma companies across Europe and North America, including AstraZeneca, Novartis and UCB across multiple therapeutic areas.
Launched in 2012 by founders Bruce Hellman and Ben James, and now a world leader in the real-world evidence data capture field, uMotif has utilised modern technology to build a cloud-based, user–friendly platform, available on any device.
Historically, patient data capture has relied on provisioned devices, paper forms or been neglected entirely, but uMotif’s revolutionary platform and industry leading patient engagement rates signal a new breakthrough in technological innovation in the sector.
The latest investment will be used to scale up the company’s team and build on the capabilities of the product, such as new language integration. Having established a strong client base in Europe and North America, which includes global pharma companies, leading academic medical centres and contract research organisations, uMotif is also looking to expand into the Asia Pacific market.
Andrew Elder, partner at Albion Capital, said: “uMotif has developed a game-changing product for the health and pharma industries, opening new doors to creating more successful treatments, enabled through unprecedented patient engagement. Since launching five years ago, Bruce and Ben have done a fantastic job in positioning uMotif as one of the world leaders in a field which is notoriously hard to penetrate with new technology.
“We are hugely excited about the growth potential of the company moving forward and, as the first institutional investor to come aboard, we look forward to working with the team to fulfil their expansion strategy.”
Bruce Hellman, CEO, uMotif, said: “We’re delighted to secure this round of funding. We see this investment as adding rocket fuel to fire that’s already burning brightly. It will enable us to bring on even more world class talent and remain at the forefront of patient-centric technology.”